Plain-English translation of NCT05789303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , combined with three other medications (, , and ), can help people with multiple myeloma that has returned or become resistant to previous treatments. Researchers want to understand if this medication combination is both safe and effective for patients whose cancer has already been treated multiple times. The study includes two groups: people who have and have not previously received CAR T-cell therapy.
Multiple myeloma often comes back or stops responding to standard treatments, leaving patients with limited options. This medication is being tested because doctors hope the new combination might work for people whose cancer has become resistant to current standard therapies, even advanced ones like CAR T-cell therapy.
You likely qualify if…
You likely don't qualify if…
You will receive the four-medication combination as part of regular clinic visits over 6 to 24 months, depending on how your cancer responds. The study involves regular blood tests and scans to monitor how the treatment is working and to watch for any side effects. You'll be assigned to one of two groups based on whether you've had CAR T-cell therapy before, but both groups receive the same treatment combination.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States